7.36

2.65% 0.19

Pre-market: 7.35 -0.01 -0.14%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is traded at $7.36, with a volume of 1.05M. It is up +2.65% in the last 24 hours and down -21.54% over the past month. Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Previous Close:

$7.17

Open:

$7.3

24h Volume:

1.05M

Relative Volume:

0.95

Market Cap:

$455.76M

Revenue:

$170.16M

Net Income/Loss:

$-312.76M

P/E Ratio:

-1.2949

EPS:

-5.6837

Net Cash Flow:

$-178.72M

1W Performance:

+13.41%

1M Performance:

-21.54%

6M Performance:

-34.58%

1Y Performance:

+3.37%

1-Day Range:

$7.2645

$7.65

1-Week Range:

$6.31

$7.65

52-Week Range:

$5.00

$17.58

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(877) 442-5362

Address

27 DRYDOCK AVENUE, BOSTON

Employee

485

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

DNA's Discussions on Twitter

Compare DNA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNA Ginkgo Bioworks Holdings Inc	7.36	455.76M	170.16M	-312.76M	-178.72M	-5.6837
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-15-24	Downgrade	BTIG Research	Neutral → Sell
May-10-24	Downgrade	William Blair	Mkt Perform → Underperform
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Mar 24, 2026

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2025 earnings call transcript - MSN

Mar 24, 2026

(DNA) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 24, 2026

Mar 22, 2026